METASTX

MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK)... MetasTx is creating treatments that prevent and treat prostate cancer metastasis without the devastating effects of today's Androgen deprivation therapies.

Also known as: MetasTx, LLC

Primary location: Pittsburgh United States